Interleukin-2 for Treating Autism Spectrum Disorder

USPTO published a patent application (US20260092095A1) for the use of interleukin-2 in treating autism spectrum disorder. The patent covers administration of IL-2 to subjects with ASD, prevention of ASD in at-risk children, and maternal administration during pregnancy to prevent ASD in offspring. Assignee is INSERM (France), with inventors including David Klaatzman, Pierre Ellul, Michelle Rosenzwajg, Richard Delorme, and Gwladys Fourcade. The filing date was September 12, 2022 (Application No. 19110627).

This is a routine patent publication providing public notice of a patent application. No immediate compliance actions are required. Pharmaceutical companies developing immunological therapies or treatments for neurodevelopmental disorders may wish to review for potential licensing needs or freedom-to-operate analysis. Researchers in the IL-2 or autism treatment space should monitor this application's prosecution for potential overlaps with their own IP strategies.